Myriad Genetics, Inc.
MYGN
$4.81
-$0.34-6.60%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 1.99% | -3.47% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 1.99% | -3.47% | |||
| Cost of Revenue | 1.78% | 0.98% | |||
| Gross Profit | 2.09% | -5.27% | |||
| SG&A Expenses | -10.51% | 0.14% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -7.07% | 1.51% | |||
| Operating Income | 87.12% | -86.40% | |||
| Income Before Tax | 66.03% | 92.08% | |||
| Income Tax Expenses | -183.33% | 1,300.00% | |||
| Earnings from Continuing Operations | 71.17% | 91.71% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 71.17% | 91.71% | |||
| EBIT | 87.12% | -86.40% | |||
| EBITDA | 189.72% | -768.75% | |||
| EPS Basic | 71.22% | 91.76% | |||
| Normalized Basic EPS | 76.41% | -87.33% | |||
| EPS Diluted | 71.22% | 91.76% | |||
| Normalized Diluted EPS | 76.41% | -87.33% | |||
| Average Basic Shares Outstanding | 0.21% | 0.65% | |||
| Average Diluted Shares Outstanding | 0.21% | 0.65% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||